破骨细胞促进多发性骨髓瘤免疫抑制微环境的形成

安刚; 邱录贵

doi:10.13201/j.issn.1004-2806.2017.07.002

破骨细胞促进多发性骨髓瘤免疫抑制微环境的形成

安刚,
邱录贵^,

- 中国医学科学院血液病医院血液学研究所淋巴瘤中心(天津, 300020)
基金项目:
国家自然科学基金重点项目(No:81630007)

国家自然科学基金面上项目(No:81670202)

详细信息

通讯作者: 邱录贵,E-mail:qiulg@ihcams.ac.cn

中图分类号: R733.3

收稿日期: 2017-06-26

Comments on “Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication”

AN Gang,
QIU Lugui^,

More Information

Corresponding author: QIU Lugui, E-mail: qiulg@ihcams.ac.cn

Received Date: 26 June 2017

摘要

- 多发性骨髓瘤 /
- 免疫抑制微环境 /
- 破骨细胞
- multiple myeloma /
- immune suppressive microenvironment /
- osteoclasts

HTML全文

参考文献(14)

[1]	Terpos E,Morgan G,Dimopoulos MA,et al.International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease[J].J Clin Oncol,2013,31:2347-2357.
[2]	Takayanagi H.New developments in osteoimmunology[J].Nat Rev Rheumatol,2012,8:684-689.
[3]	Takayanagi H.Osteoimmunology and the effects of the immune system on bone[J].Nat Rev Rheumatol,2009,5:667-676.
[4]	Li S,Zhai Q,Zou D,et al.A pivotal role of bone remodeling in granulocyte colony stimulating factor induced hematopoietic stem/progenitor cells mobilization[J].J Cell Physiol,2013,228:1002-1009.
[5]	Charles JF,Aliprantis AO.Osteoclasts:more than 'bone eaters'[J].Trends Mol Med,2014,20:449-459.
[6]	Topalian SL,Drake CG,Pardoll DM.Immune checkpoint blockade:a common denominator approach to cancer therapy[J].Cancer Cell,2015,27:450-461.
[7]	Ribas A.Releasing the brakes on cancer immunotherapy[J].N Engl J Med,2015,373:1490-1492.
[8]	Sharma P,Allison JP.Immune checkpoint targeting in cancer therapy:toward combination strategies with curative potential[J].Cell,2015,161:205-214.
[9]	Cui W,Cuartas E,Ke J,et al.CD200 and its receptor,CD200R,modulate bone mass via the differentiation of osteoclasts[J].Proc Natl Acad Sci U S A,2007,104:14436-14441.
[10]	Coles SJ,Wang EC,Man S,et al.CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia[J].Leukemia,2011,25:792-799.
[11]	Tai YT,Mayes PA,Acharya C,et al.Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma[J].Blood,2014,123:3128-3138.
[12]	Tai YT,Acharya C,An G,et al.APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment[J].Blood,2016,127:3225-3236.
[13]	Prabhala RH,Fulciniti M,Pelluru D,et al.Targeting IL-17A in multiple myeloma:a potential novel therapeutic approach in myeloma[J].Leukemia,2016,30:379-389.
[14]	Prabhala RH,Pelluru D,Fulciniti M,et al.Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma[J].Blood,2010,115:5385-5392.